DGAP-News

Sangui BioTech International Inc.: New expert consensus underlines the outstanding effect of Granulox in chronic wounds - Seite 2

or in case of complications.

The expert consensus clarifies that Granulox is well suited to provide
wounds with additional oxygen. In addition, the healing processes of
hypoxic wounds can be supported, especially if a sufficient improvement in
wound healing by standard therapies could not be achieved. Thus the
publication once again shows that Granulox should be integrated as a
treatment method in the care of chronic wounds.

"We are delighted that such a high-caliber international expert group
emphasizes the role of Granulox in modern wound treatment and calls for a
systematic use in non-healing wounds," commented Michael Sander, Managing
Director of Sastomed GmbH, to which Sangui BioTech GmbH has licensed the
worldwide distribution rights for the wound spray Granulox.

The complete article is available as downloadable at: http://granulox.de/
downloads/Wundmanagement_5_2016_Konsensus_DE.pdf

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB venture stage marketplace for early
stage and developing U.S. and international companies (OTCQB: SGBI).
Companies are current in their reporting and undergo an annual verification
and management certification process. Sangui shares also trade on the OTC
markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
purpose is to provide financing and access to the capital markets for the
enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: [phone]
e-mail: [e-mail]

Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such forward-
looking statements. Unless required by law, the Company undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.


---------------------------------------------------------------------------

25.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

524269 25.11.2016